BC
JAZZ icon

Brookfield Corp’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brookfield Corp’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-63,331
Closed -$10.1M – 722
2022
Q4 		$10.1M Buy
63,331
+54,145
+589% +$7.94M 0.04% 149
2022
Q3 		$1.22M Buy
+9,186
New +$1.4M ﹤0.01% 516

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brookfield Corp's JAZZ Position: Q1 2023 in Review

Brookfield Corp sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 63,331 shares — an estimated $10.1M sold.

Brookfield Corp first reported a position in JAZZ in Q3 2022 and held it in 2 quarters. The position peaked at $10.1M in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • Brookfield Corp reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Brookfield Corp sold 63,331 Jazz Pharmaceuticals shares in Q1 2023, an estimated $10.1M.
  • Brookfield Corp first reported a position in Jazz Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Brookfield Corp's Jazz Pharmaceuticals position peaked at $10.1M in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.